The Global Antibiotics Market is estimated to reach USD 65.81 Billion by 2027, according to a new report by Reports and Data. This can be mainly associated with the growing incidences of infectious diseases such as pneumonia, HIV/AIDS, malaria, and tuberculosis, along with technological advancements that are expected to become the most common growth factors globally in the coming years.
Expanding efforts initiated by the key companies for the development of advanced products will boost market growth. A report by the Pew Charitable Trust states, about 37 promising molecules were investigated within the U.S. market in March 2016. Majority of which are in clinical trials phase II and are expected to hit the market in the coming years.
Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/1377
Moreover, supportive government enactments, such as the GAIN (Generating Antibiotics Incentives Now) Act, are anticipated to facilitate the approval process. GAIN Act has plans, which promote the advancement of therapies against antibiotic-resistant pathogens. Diarrhea is one of the leading causes of death among children across the globe, and it requires antibiotic mediation to reduce the death rate. Other infectious diseases that may boost the growth of the market are pneumonia, HIV/AIDS, malaria, and tuberculosis. Moreover, the spread of new infections, such as Ebola and Zika virus, are promoting the development and growth of the antibiotics market.
Due to the presence of key players, favorable reimbursement policies, and rising incidences of chronic diseases, along with several initiatives taken by the governments, North America accounts for the largest share of around 33.5% of the market in 2019.
Further key findings from the report suggest
- Antibiotics are a combination of medicines used in the treatment of infections or diseases caused by bacteria, germs, and some parasites-by restraining the growth of microorganisms or destroying them.
- Antibiotics are also known as antimicrobials or antibacterial.
- An increase in the prevalence of persistent and infectious diseases across the globe and the ability of antibiotics to treat a broad spectrum of bacterial infections have led to the accelerated growth of the global market.
- Since the development of the antibiotic penicillin in 1920, several antibiotic compounds have been used to treat various bacterial infections.
- Growing population, increasing rates of chronic diseases, and rising healthcare expenditures are the fundamental factors that are boosting the growth of the market across the globe.
- The development of various antiviral drugs, which hinder transcription and reverse transcription methods, is expected to boost market growth.
- DNA synthesis inhibitors of the type segment are anticipated to grow at the highest rate of 4.1% during the forecast period.
- Innovative product development and collaborative developments are some critical strategic initiatives taken by the players in this industry to point their mark in the competition.
- The presence of unique diagnostic and therapeutic medical technologies that enable quick and accurate diagnosis is the primary factor for the growth of this segment.
- The indiscriminate and continued use of antibiotics in the last few years has led to the growth of antibiotic-resistant bacteria and pathogens.
- The carbapenems product type accounted for the largest share of around 47.6% of the market in 2019.
- Increasing prevalence of bloodstream infections, pneumonia, and Urinary Tract Infections (UTI) is expected to encourage the usage of carbapenems.
- Oral antibiotics offer fewer side effects, moderate cost, improved antimicrobial properties, and are comfortable for patients.
- Oral mode of administration accounts for the largest share of 37.6% in 2019.
- The retail pharmacies among the end-user segment accounted for the largest share of around 38.8% of the market in 2019.
- Europe accounted for a market share of over 26.3% in 2019 and is expected to grow at a rate of 3.9% during the forecast period.
- Key participants include Bristol-Myers Squibb Co., AstraZeneca plc, The Menarini Group, GlaxoSmithKline plc, Bayer HealthCare AG, Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd., and Sanofi, among others.
Order Your Copy Now (Customized report delivered as per your specific requirement)@ https://www.reportsanddata.com/checkout-form/1377
For the purpose of this study, Reports and Data segments the Global Antibiotics Market on the basis of Type, End user, Product, Administration mode, and Region:
Type Outlook (Revenue, USD Million; 2017-2027)
- RNA Synthesis Inhibitors
- DNA Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- Mycolic Acid Inhibitors
End-user Outlook (Revenue, USD Million; 2017-2027)
- Retail pharmacies
- Online pharmacies
- Hospital pharmacies
Product Outlook (Revenue, USD Million; 2017-2027)
- Carbapenems
- Penicillin
- Fluoroquinolones
- Macrolides
- Others
Administration mode Outlook (Revenue, USD Million; 2017-2027)
- Oral
- Topical
- Sublingual
- Inhalation
- Others
Regional Outlook (Revenue, USD Million; 2017-2027)
- North America
- S.
- Europe
- France
- K.
- Asia Pacific
- China
- India
- Japan
- Latin America
- Brazil
- Middle East & Africa
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/antibiotics-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John Watson
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
